{"altmetric_id": 79974082, "counts": {"readers": {"citeulike": "0", "mendeley": "143", "connotea": "0"}, "total": {"posts_count": 107}, "twitter": {"unique_users_count": 64, "posts_count": 88}, "news": {"unique_users_count": 18, "unique_users": ["sciencenewsnet_in", "newswise", "science_media_centre", "foreign_affairs_new_zealand", "gazeta_ru", "futurity", "digital_journal", "economy_watch", "pr_newswire", "ticker_tech", "finanzen_ch", "vb_profiles", "benzinga", "the_street", "kpvi", "wfmz_tv_69", "profitquotes_com", "spoke"], "posts_count": 18}, "blogs": {"unique_users_count": 1, "unique_users": [51890], "posts_count": 1}}, "citation": {"altmetric_jid": "532721422a83ee84788b4567", "authors": ["de Assis, Rafael R.", "Jain, Aarti", "Nakajima, Rie", "Jasinskas, Algis", "Felgner, Jiin", "Obiero, Joshua M.", "Adenaiye, Oluwasanmi", "Tai, Sheldon", "Hong, Filbert", "Norris, Philip J.", "Stone, Mars", "Simmons, Graham", "Bagri, Anil", "Schreiber, Martin", "Buser, Andreas", "Holbro, Andreas", "Battegay, Manuel", "Hosimer, Philip", "Noesen, Charles", "Milton, Donald K.", "Davies, D. Huw", "Contestable, Paul", "Corash, Laurence M.", "Busch, Michael P.", "Felgner, Philip L.", "Khan, Saahir"], "doi": "10.1101/2020.04.15.043364", "first_seen_on": "2020-04-17T09:37:35+00:00", "issns": [], "journal": "bioRxiv", "last_mentioned_on": 1605013868, "links": ["https://www.biorxiv.org/content/10.1101/2020.04.15.043364v1", "https://doi.org/10.1101/2020.04.15.043364", "https://www.biorxiv.org/content/10.1101/2020.04.15.043364v1.full.pdf", "https://www.biorxiv.org/content/10.1101/2020.04.15.043364v1.article-info", "https://www.biorxiv.org/content/10.1101/2020.04.15.043364v1?rss=1&utm_source=dlvr.it&utm_medium=twitter", "https://www.biorxiv.org/content/10.1101/2020.04.15.043364v2"], "pdf_url": "https://www.biorxiv.org/content/biorxiv/early/2020/04/17/2020.04.15.043364.full.pdf", "pmid": "32511302", "publisher": "Cold Spring Harbor Laboratory", "title": "Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Blood using a Coronavirus Antigen Microarray", "type": "article", "mendeley_url": "https://www.mendeley.com/catalogue/1aa6a3e5-82e2-3487-aa1d-09bdc9273413/"}, "altmetric_score": {"score": 162.904, "score_history": {"1y": 91.95, "6m": 0, "3m": 0, "1m": 0, "1w": 0, "6d": 0, "5d": 0, "4d": 0, "3d": 0, "2d": 0, "1d": 0, "at": 162.904}, "context_for_score": {"all": {"total_number_of_other_articles": 17673294, "mean": 9.436077173952, "rank": 139509, "this_scored_higher_than_pct": 99, "this_scored_higher_than": 17534446, "rank_type": "exact", "sample_size": 17673294, "percentile": 99}, "similar_age_3m": {"total_number_of_other_articles": 284602, "mean": 21.156196112465, "rank": 5772, "this_scored_higher_than_pct": 97, "this_scored_higher_than": 278832, "rank_type": "exact", "sample_size": 284602, "percentile": 97}, "this_journal": {"total_number_of_other_articles": 120516, "mean": 13.887966012812, "rank": 801, "this_scored_higher_than_pct": 99, "this_scored_higher_than": 119720, "rank_type": "exact", "sample_size": 120516, "percentile": 99}, "similar_age_this_journal_3m": {"total_number_of_other_articles": 8321, "mean": 20.462022593438, "rank": 129, "this_scored_higher_than_pct": 98, "this_scored_higher_than": 8193, "rank_type": "exact", "sample_size": 8321, "percentile": 98}}}, "demographics": {"poster_types": {"member_of_the_public": 45, "researcher": 16, "practitioner": 3}, "users": {"twitter": {"cohorts": {"Members of the public": 44, "Practitioners (doctors, other healthcare professionals)": 3, "Scientists": 17}}, "mendeley": {"by_status": {"Student  > Postgraduate": 6, "Professor > Associate Professor": 4, "Researcher": 27, "Student  > Master": 14, "Student  > Ph. D. Student": 14, "Professor": 5, "Student  > Bachelor": 20, "Student  > Doctoral Student": 6, "Lecturer": 4, "Other": 6, "Librarian": 4, "Unspecified": 5}, "by_discipline": {"Materials Science": 1, "Medicine and Dentistry": 36, "Social Sciences": 2, "Mathematics": 3, "Pharmacology, Toxicology and Pharmaceutical Science": 2, "Environmental Science": 1, "Unspecified": 5, "Engineering": 9, "Chemistry": 2, "Neuroscience": 1, "Energy": 1, "Economics, Econometrics and Finance": 1, "Immunology and Microbiology": 11, "Computer Science": 2, "Agricultural and Biological Sciences": 11, "Nursing and Health Professions": 1, "Linguistics": 1, "Business, Management and Accounting": 2, "Biochemistry, Genetics and Molecular Biology": 19, "Veterinary Science and Veterinary Medicine": 2}}}, "geo": {"twitter": {"US": 17, "GB": 4, "HK": 1, "FR": 1, "DE": 1, "EC": 3, "CA": 1, "CL": 1, "CO": 1, "IM": 1, "SE": 1, "CH": 1, "LB": 2, "IQ": 1, "PH": 1, "VN": 1}}}, "posts": {"twitter": [{"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "1949132852"}, "tweet_id": "1251059907811520512"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "1054460958226157568"}, "tweet_id": "1251059908654620672"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "1522181906"}, "tweet_id": "1251060312276717575"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "1182387594312798209"}, "tweet_id": "1251065420062343172"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "635567256"}, "tweet_id": "1251071074328104960"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "635567256"}, "tweet_id": "1251071133467672577"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "635567256"}, "tweet_id": "1251071450976595968"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "635567256"}, "tweet_id": "1251071552344543233"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "635567256"}, "tweet_id": "1251071606652362752"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "580633644"}, "tweet_id": "1251071610154450944"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "635567256"}, "tweet_id": "1251071706896257026"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "635567256"}, "tweet_id": "1251072017031409664"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "3142088601"}, "tweet_id": "1251113946590973952"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "427877977"}, "tweet_id": "1251114285150932994"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "1344890352"}, "tweet_id": "1251127629375254529"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "961643882"}, "tweet_id": "1251134211546701827"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "15504380"}, "tweet_id": "1251139929310146561"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "1080590070313295874"}, "tweet_id": "1251177297060618240"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "786975175"}, "tweet_id": "1251177478510403584"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "2296454820"}, "tweet_id": "1251223650725920769"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "1415091"}, "tweet_id": "1251249892111990784"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "1244711417657376768"}, "tweet_id": "1251336098200072192"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "738023789439635457"}, "tweet_id": "1251338673641017344"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "1250060162540412929"}, "tweet_id": "1251374882123911168"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "1236992477829181440"}, "tweet_id": "1251431738431156227"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "4901919879"}, "tweet_id": "1251442165542268928"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "4901919879"}, "tweet_id": "1251442193497231362"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "4901919879"}, "tweet_id": "1251442896852652033"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "2296454820"}, "tweet_id": "1251564403776000001"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "480875170"}, "tweet_id": "1251684600126099457"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "291561003"}, "tweet_id": "1251686053888524290"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "2742938653"}, "tweet_id": "1251688185689706499"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "33177553"}, "tweet_id": "1251891711778922499"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "1243873436033671168"}, "tweet_id": "1252000548766617608"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "1243873436033671168"}, "tweet_id": "1252008515528323072"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "92010665"}, "tweet_id": "1252017267929427968"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "147295417"}, "tweet_id": "1252046867279593473"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "28358443"}, "tweet_id": "1252046924384890880"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "999100031239118853"}, "tweet_id": "1252048843304288261"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "1066487221"}, "tweet_id": "1252051987224559618"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "26587336"}, "tweet_id": "1252053116327002113"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "134146548"}, "tweet_id": "1252056970913353729"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "1049075800996286464"}, "tweet_id": "1252059924047245312"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "766431397"}, "tweet_id": "1252085118086283267"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "985699594850918400"}, "tweet_id": "1252090270088216577"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "3360212164"}, "tweet_id": "1252108701168734208"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "1067401595229532165"}, "tweet_id": "1252114713862975488"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "2179772732"}, "tweet_id": "1252120235257270275"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "118735564"}, "tweet_id": "1252129986762412036"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "786118672343457793"}, "tweet_id": "1252139277108097026"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "1141484932025311233"}, "tweet_id": "1252148488856457223"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "147295417"}, "tweet_id": "1252288683010658304"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "1242854825429209093"}, "tweet_id": "1252289814440873986"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "208072082"}, "tweet_id": "1252294770707369989"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "310905714"}, "tweet_id": "1252296151182700545"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "742674795322585088"}, "tweet_id": "1252315028587532298"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "470099461"}, "tweet_id": "1252332969093738504"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "4056200494"}, "tweet_id": "1252333643281977344"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "147295417"}, "tweet_id": "1252342033953353734"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "311678902"}, "tweet_id": "1252342574699868168"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "730745464136466432"}, "tweet_id": "1252345210777948160"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "1066487221"}, "tweet_id": "1252347100647452684"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "3218785501"}, "tweet_id": "1252359040379662337"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "545478058"}, "tweet_id": "1252377555404902404"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "2396167723"}, "tweet_id": "1252404696746037248"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "15504380"}, "tweet_id": "1252406125137326080"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "3319721843"}, "tweet_id": "1252436598786076672"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "766431397"}, "tweet_id": "1252444091033489408"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "766431397"}, "tweet_id": "1252444148558450688"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "1236992477829181440"}, "tweet_id": "1252474605291347969"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "2770314369"}, "tweet_id": "1252906801210765313"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "795630211"}, "tweet_id": "1253138125955764227"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "2358210234"}, "tweet_id": "1253923205414137856"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "2358210234"}, "tweet_id": "1253923419730534401"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "147295417"}, "tweet_id": "1256343146629341184"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "3319721843"}, "tweet_id": "1256345442528493576"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "766431397"}, "tweet_id": "1256431888220241925"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "4901919879"}, "tweet_id": "1260536607230308352"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "4901919879"}, "tweet_id": "1260536677967302656"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "4901919879"}, "tweet_id": "1260538465583869953"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "1265336030833422337"}, "tweet_id": "1269038995880570881"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "835178526093488133"}, "tweet_id": "1273657147956572162"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "403657616"}, "tweet_id": "1273659405767147523"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "1250158122024308736"}, "tweet_id": "1287270627909332992"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "1208294580438929409"}, "tweet_id": "1287273498348605443"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "65331455"}, "tweet_id": "1291748345208340483"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "898265938650439680"}, "tweet_id": "1306404327783903232"}, {"license": "gnip", "citation_ids": [79974082], "author": {"tweeter_id": "1231507812175564800"}, "tweet_id": "1326150397938053120"}], "news": [{"title": "DARPA-funded microchip technology optimizes convalescent plasma therapy for COVID-19 patients", "url": "https://sciencenewsnet.in/darpa-funded-microchip-technology-optimizes-convalescent-plasma-therapy-for-covid-19-patients/", "license": "public", "citation_ids": [79974082], "posted_on": "2020-04-17T16:10:05+00:00", "summary": "Post Views: 2 Irvine, CA \u2013 April 17, 2020 A consortium of California scientists from government, academia and business today published an initial manuscript describing a novel approach to prepare convalescent plasma for COVID-19 patients in BioRxiv.", "author": {"name": "Sciencenewsnet.in", "url": "https://sciencenewsnet.in/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/005/084/normal/IN.PNG?1578485787"}}, {"title": "DARPA-funded microchip technology optimizes convalescent plasma therapy for COVID-19 patients", "url": "http://ct.moreover.com/?a=41902654373&p=1pl&v=1&x=yaojmbn7bS_gS5daUa3Lxw", "license": "public", "citation_ids": [79974082], "posted_on": "2020-04-17T20:45:49+00:00", "summary": "\u2013 A consortium of California scientists from government, academia and business today published an initial manuscript describing a novel approach to prepare convalescent plasma for COVID-19 patients in BioRxiv.", "author": {"name": "Newswise", "url": "http://www.newswise.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/000/200/normal/image.png?1370251547"}}, {"title": "expert reaction to new preprint on antibody testing for SARS-COV-2", "url": "https://www.sciencemediacentre.org/expert-reaction-to-new-preprint-on-antibody-testing-for-sars-cov-2/", "license": "public", "citation_ids": [94019801, 79974082, 94016680], "posted_on": "2020-04-21T09:43:06+00:00", "summary": "April 21, 2020 A preprint, posted to MedRxiv, reports on antibody testing for SARS-COV-2.", "author": {"name": "Science Media Centre", "url": "http://www.sciencemediacentre.org/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/000/104/normal/image.png?1369925910"}}, {"title": "MIL-OSI United Kingdom: expert reaction to new preprint on antibody testing for SARS-COV-2", "url": "http://ct.moreover.com/?a=41929188886&p=1pl&v=1&x=-DwoY5huiB9eqoQdRpnYqw", "license": "public", "citation_ids": [94019801, 79974082, 94016680], "posted_on": "2020-04-21T09:58:21+00:00", "summary": "Source: United Kingdom \u2013 Executive Government & Departments April 21, 2020 A preprint, posted to MedRxiv, reports on antibody testing for SARS-COV-2.", "author": {"name": "Foreign Affairs New Zealand", "url": "http://foreignaffairs.co.nz/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/827/normal/Screen_Shot_2016-01-27_at_10.47.41.png?1453891760"}}, {"title": "\u0421\u043e\u0437\u0434\u0430\u043d \u043c\u0438\u043a\u0440\u043e\u0447\u0438\u043f \u0434\u043b\u044f \u0432\u044b\u044f\u0432\u043b\u0435\u043d\u0438\u044f \u0432 \u043a\u0440\u043e\u0432\u0438 \u0430\u043d\u0442\u0438\u0442\u0435\u043b \u043a COVID-19", "url": "http://ct.moreover.com/?a=41929965434&p=1pl&v=1&x=Jf9W2xdZgKUppyt4nrJ77A", "license": "public", "citation_ids": [79974082], "posted_on": "2020-04-21T11:24:55+00:00", "summary": "\u0423\u0447\u0435\u043d\u044b\u0435 \u0438\u0437 \u0421\u0428\u0410 \u0438 \u0428\u0432\u0435\u0439\u0446\u0430\u0440\u0438\u0438 \u0440\u0430\u0437\u0440\u0430\u0431\u043e\u0442\u0430\u043b\u0438 \u043c\u0438\u043a\u0440\u043e\u0447\u0438\u043f \u0434\u043b\u044f \u0432\u044b\u044f\u0432\u043b\u0435\u043d\u0438\u044f \u0432 \u043a\u0440\u043e\u0432\u0438 \u0430\u043d\u0442\u0438\u0442\u0435\u043b \u043a \u0440\u0430\u0437\u043b\u0438\u0447\u043d\u044b\u043c \u043a\u043e\u0440\u043e\u043d\u0430\u0432\u0438\u0440\u0443\u0441\u0430\u043c, \u0432 \u0442\u043e\u043c \u0447\u0438\u0441\u043b\u0435 \u043a SARS-CoV-2.", "author": {"name": "Gazeta.ru", "url": "http://www.gazeta.ru/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/000/517/normal/Screen_Shot_2016-01-13_at_16.37.27.png?1452703065"}}, {"title": "Antibody test makes picking COVID-19 plasma donors easier - Futurity", "url": "https://www.futurity.org/convalescent-plasma-2350472/?utm_source=rss&utm_medium=rss&utm_campaign=convalescent-plasma-2350472", "license": "public", "citation_ids": [79974082], "posted_on": "2020-04-28T17:24:16+00:00", "summary": "A new microchip technology could optimize convalescent plasma therapy for COVID-19 patients, according to a new study.", "author": {"name": "Futurity", "url": "http://www.futurity.org/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/030/normal/Screen_Shot_2014-07-16_at_11.51.38.png?1405507934"}}, {"title": "Nanommune Partners With Velox Biosystems to Offer Laboratory Testing of COVID-19 Serological Assays", "url": "http://ct.moreover.com/?a=42495811070&p=1pl&v=1&x=gKxrsujo4JSZpN9_Oam7Cg", "license": "public", "citation_ids": [79974082, 82639539], "posted_on": "2020-07-01T17:22:44+00:00", "summary": "- ( Newswire.com ) \u200b\u200b\u200bNanommune Inc. and Velox Biosystems, Inc. have announced a partnership to bring to market rapid, high-throughput laboratory testing and consulting services for clinicians, laboratories, and researchers to accelerate their use\u2026", "author": {"name": "Digital Journal", "url": "http://www.digitaljournal.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/000/223/normal/image.png?1371424893"}}, {"title": "Nanommune Partners With Velox Biosystems to Offer Laboratory Testing of COVID-19 Serological Assays", "url": "http://ct.moreover.com/?a=42496286345&p=1pl&v=1&x=XqthoISuI5rLT0kJzEZ3Hw", "license": "public", "citation_ids": [79974082, 82639539], "posted_on": "2020-07-01T18:40:27+00:00", "summary": "- ( Newswire.com ) \u200b\u200b\u200bNanommune Inc. and Velox Biosystems, Inc. have announced a partnership to bring to market rapid, high-throughput laboratory testing and consulting services for clinicians, laboratories, and researchers to accelerate their use\u2026", "author": {"name": "Economy Watch", "url": "http://www.economywatch.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/918/normal/Screen_Shot_2016-01-27_at_14.58.39.png?1453906769"}}, {"title": "Nanommune Partners With Velox Biosystems to Offer Laboratory Testing of COVID-19 Serological Assays", "url": "http://ct.moreover.com/?a=42496615897&p=1pl&v=1&x=akLZiwya9aSKzTKocllGoQ", "license": "public", "citation_ids": [79974082, 82639539], "posted_on": "2020-07-01T19:32:00+00:00", "summary": "/PRNewswire/ --. and Velox Biosystems, Inc. have announced a partnership to bring to market rapid, high-throughput laboratory testing and consulting services for clinicians, laboratories, and researchers to accelerate their use and adoption of\u2026", "author": {"name": "PR Newswire", "url": "http://www.prnewswire.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/545/normal/Screen_Shot_2016-01-06_at_16.29.18.png?1452097789"}}, {"title": "Nanommune Partners With Velox Biosystems to Offer Laboratory Testing of COVID-19 Serological Assays", "url": "http://ct.moreover.com/?a=42496619675&p=1pl&v=1&x=P8xzbhMde7vxwcqNGAN5Jg", "license": "public", "citation_ids": [79974082, 82639539], "posted_on": "2020-07-01T19:37:17+00:00", "summary": "IRVINE, Calif., July 1, 2020 /PRNewswire/ -- Nanommune Inc. and Velox Biosystems, Inc.", "author": {"name": "Ticker Tech", "url": "http://www.tickertech.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/724/normal/Screen_Shot_2016-01-26_at_15.37.40.png?1453822700"}}, {"title": "Nanommune Partners With Velox Biosystems to Offer Laboratory Testing of COVID-19 Serological Assays", "url": "http://ct.moreover.com/?a=42496628889&p=1pl&v=1&x=L_Y9QImzaRQ_kAy8NmnobQ", "license": "public", "citation_ids": [79974082, 82639539], "posted_on": "2020-07-01T19:32:00+00:00", "summary": "/PRNewswire/ -- Nanommune Inc. and Velox Biosystems, Inc. have announced a partnership to bring to market rapid, high-throughput laboratory testing and consulting services for clinicians, laboratories, and researchers to accelerate their use and\u2026", "author": {"name": "Finanzen.ch", "url": "https://www.finanzen.ch/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/573/normal/Capture26.PNG?1575886265"}}, {"title": "Nanommune Partners With Velox Biosystems to Offer Laboratory Testing of COVID-19 Serological Assays", "url": "http://ct.moreover.com/?a=42496664050&p=1pl&v=1&x=Ht5nLQq2TYVTYBVsJ6983A", "license": "public", "citation_ids": [79974082, 82639539], "posted_on": "2020-07-01T19:44:52+00:00", "summary": "/PRNewswire/ -- Nanommune Inc. and Velox Biosystems, Inc. have announced a partnership to bring to market rapid, high-throughput laboratory testing and consulting services for clinicians, laboratories, and researchers to accelerate their use and\u2026", "author": {"name": "VB Profiles", "url": "https://www.vbprofiles.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/839/normal/58.JPG?1576557158"}}, {"title": "Nanommune Partners With Velox Biosystems to Offer Laboratory Testing of COVID-19 Serological Assays", "url": "http://ct.moreover.com/?a=42496669481&p=1pl&v=1&x=rlfWFJB8Vz-a814q3fFuMQ", "license": "public", "citation_ids": [79974082, 82639539], "posted_on": "2020-07-01T19:32:00+00:00", "summary": "/PRNewswire/ -- Nanommune Inc. and Velox Biosystems, Inc. have announced a partnership to bring to market rapid, high-throughput laboratory testing and consulting services for clinicians, laboratories, and researchers to accelerate their use and\u2026", "author": {"name": "Benzinga", "url": "http://www.benzinga.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/738/normal/Screen_Shot_2016-01-26_at_15.59.27.png?1453824001"}}, {"title": "Nanommune Partners With Velox Biosystems To Offer Laboratory Testing Of COVID-19 Serological Assays", "url": "http://ct.moreover.com/?a=42496724271&p=1pl&v=1&x=jN3JAOfdq7J1jlbScbP4dA", "license": "public", "citation_ids": [79974082, 82639539], "posted_on": "2020-07-01T19:32:00+00:00", "summary": "/PRNewswire/ -- Nanommune Inc. IRVINE, Calif., July 1, 2020 /PRNewswire/ -- Nanommune Inc.", "author": {"name": "The Street", "url": "http://www.thestreet.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/809/normal/Screen_Shot_2016-01-27_at_10.05.56.png?1453889412"}}, {"title": "Nanommune Partners With Velox Biosystems to Offer Laboratory Testing of COVID-19 Serological Assays", "url": "http://ct.moreover.com/?a=42496738679&p=1pl&v=1&x=r9TvrwPCfaOx2-j5c7tmEw", "license": "public", "citation_ids": [79974082, 82639539], "posted_on": "2020-07-01T19:32:00+00:00", "summary": "/PRNewswire/ -- Nanommune Inc. and Velox Biosystems, Inc. have announced a partnership to bring to market rapid, high-throughput laboratory testing and consulting services for clinicians, laboratories, and researchers to accelerate their use and\u2026", "author": {"name": "KPVI", "url": "https://www.kpvi.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/663/normal/Capture_kvpi.PNG?1576132656"}}, {"title": "Nanommune Partners With Velox Biosystems to Offer Laboratory Testing of COVID-19 Serological Assays", "url": "http://ct.moreover.com/?a=42496742127&p=1pl&v=1&x=cQCUbRy3xooY_2mtZoJh1w", "license": "public", "citation_ids": [79974082, 82639539], "posted_on": "2020-07-01T19:32:00+00:00", "summary": "/PRNewswire/ -- Nanommune Inc. and Velox Biosystems, Inc. have announced a partnership to bring to market rapid, high-throughput laboratory testing and consulting services for clinicians, laboratories, and researchers to accelerate their use and\u2026", "author": {"name": "WFMZ-TV 69", "url": "https://www.wfmz.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/003/256/normal/Capture_62.PNG?1567141986"}}, {"title": "Nanommune Partners With Velox Biosystems to Offer Laboratory Testing of COVID-19 Serological Assays", "url": "http://ct.moreover.com/?a=42496774083&p=1pl&v=1&x=NWWnysANkY2WaYZMRORMCA", "license": "public", "citation_ids": [79974082, 82639539], "posted_on": "2020-07-01T20:04:25+00:00", "summary": "IRVINE, Calif., July 1, 2020 /PRNewswire/ -- Nanommune Inc. and Velox Biosystems, Inc.", "author": {"name": "ProfitQuotes.com", "url": "http://www.profitquotes.com/cgi/?a=news&ticker=a&w=&story=201908201908021405PR_NEWS_USPR_____DC29726", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/003/276/normal/logo7E.jpg?1567155044"}}, {"title": "Nanommune Partners With Velox Biosystems to Offer Laboratory Testing of COVID-19 Serological Assays", "url": "http://ct.moreover.com/?a=42496869407&p=1pl&v=1&x=Rpnr88R0DdPbt-SYD37wvw", "license": "public", "citation_ids": [79974082, 82639539], "posted_on": "2020-07-01T20:21:11+00:00", "summary": "/PRNewswire/ -- Nanommune Inc. and Velox Biosystems, Inc. have announced a partnership to bring to market rapid, high-throughput laboratory testing and consulting services for clinicians, laboratories, and researchers to accelerate their use and\u2026", "author": {"name": "Spoke", "url": "http://www.spoke.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/787/normal/Capture14.PNG?1576476237"}}], "blogs": [{"title": "Can I see your #MSCOVID19 paper?", "url": "https://multiple-sclerosis-research.org/2020/04/can-i-see-your-mscovid19-paper/?utm_source=rss&utm_medium=rss&utm_campaign=can-i-see-your-mscovid19-paper", "license": "public", "citation_ids": [77518072, 94076166, 79270043, 78895526, 79841046, 77126300, 78483245, 79078070, 94147127, 79405717, 61886793, 77979415, 78839344, 79974082, 79365385, 79213462, 94171232, 79341216, 77979068, 53217307, 77877558, 79832281, 79870624, 94018649, 79749790, 80264394, 76735567, 77268191, 77444676, 80377199, 79537530, 79125271, 79339045, 79856579, 80007216, 79339734, 94172884, 79384081, 78475417, 79336418, 77643102, 77942873, 29459677, 75354095, 77522753, 79350562, 94119066, 80099973, 80160261, 77677733, 94029875, 79707400, 79291256, 78534767, 77889433, 79935021, 79270043, 79841046, 34494767, 2540255, 77126300, 78483245, 79078070, 74364886, 79405717, 790426, 77856191, 77979415, 78839344, 79365385, 79213462, 79356495, 79341216, 7420194, 77877558, 79749790, 77083639, 2319724, 78472739, 77544948, 1030439, 77444676, 80377199, 79789887, 79537530, 74723549, 79125271, 79339045, 79856579, 79339734, 29985114, 78458035, 76793343, 79384081, 78171494, 78475417, 79336418, 77643102, 77942873, 76785735, 76312100, 78133464, 77623718, 79350562, 77727036, 94119066, 80099973, 80160261, 77677771, 79620876, 79707400, 79291256, 78534767, 79935021, 74465228], "posted_on": "2020-04-23T07:00:00+00:00", "summary": "I few days ago I mentioned not wanting to review someones COVID-19 and MS review, because it was missing published information and so I did not want to write their review. I submitted my constructive review of the paper for the authors benefit and then bow", "author": {"name": "Multiple Sclerosis Research", "url": "http://multiple-sclerosis-research.blogspot.com/", "description": "A blog for people with MS and their families, by Barts and The London School of Medicine and Dentistry."}}]}, "score": 162.904, "images": {"small": "https://badges.altmetric.com/?size=64&score=163&types=mbtttttt", "medium": "https://badges.altmetric.com/?size=100&score=163&types=mbtttttt", "large": "https://badges.altmetric.com/?size=180&score=163&types=mbtttttt"}}